Direxion Daily PLTR Bear 1X Shares

UBS and Mizuho Upgrade Palantir Ratings, Suggesting Upside Potential

Optimi Health

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

PLTR

PLTW

PLTG

PLTZ

PLTU

PLTD

PTIR

Palantir reported record U.S. growth with government revenue reaching $687 million in Q1 2026, an 84% increase year-over-year, prompting a full-year growth guidance boost to 71%. However, the company faces challenges in Europe as Germany's intelligence agency chose ChapsVision's ArgonOS, limiting its market presence. Analysts express a mixed outlook, noting potential as an AI operating system standard but cautioning against high valuations and dependence on government contracts.

- Palantir’s U.S. government revenue reached $687 million in Q1 2026, marking an 84% year-over-year increase, prompting management to raise full-year growth guidance to 71%.  
- The company faced a setback in Europe as Germany's intelligence agency chose ChapsVision over Palantir, citing data sovereignty issues.  
- While analysts recognize Palantir's potential to become a standard in AI operating systems, concerns about high valuation, slow international growth, and dependence on government contracts persist.

Palantir Tech

Roundhill PLTR WeeklyPay ETF

Leverage Shares 2X Long PLTR Daily ETF

Defiance Daily Target 2X Short PLTR ETF

Direxion Daily PLTR Bull 2X Shares

GraniteShares 2x Long PLTR Daily ETF

Palantir posts record growth but faces European market loss

PLOO

Palantir reported a record Q1 revenue of $1.63B, up 85%, with U.S. sales increasing 104% and operating margins at 60%. However, concerns about high valuations persist, with a price-to-sales ratio of 66 and a forward P/E near 100. Analysts have mixed opinions, with price targets between $70 and $255 and consensus ratings of 'Moderate Buy' to 'Buy'.

- Q1 revenue rose 85% to $1.63 billion, with U.S. sales up 104% and operating margins at 60%.  
- Shares are trading at high multiples, including a price-to-sales ratio of approximately 66 and a forward P/E near 100, which raises concerns of overpricing.  
- Analyst price targets vary from $70 to $255, and consensus ratings are between 'Moderate Buy' and 'Buy', indicating uncertainty about future gains.

Defiance Leveraged Long +Income PLTR ETF

Leverage Shares 2x Cpd Acclrtd PLTRMnETF

Palantir's blowout quarter fails to lift high-priced stock

HOOD

HOOG

GraniteShares has launched two new autocallable ETFs linked to Palantir and Robinhood, aiming to provide monthly income opportunities for investors. The GraniteShares Autocallable PLTR ETF and AHD ETF are designed to capitalize on the volatility of these popular retail stocks. Each fund has an expense ratio of 0.99% and targets periodic income through structured strategies, offering advantages like intraday liquidity and portfolio transparency.

- GraniteShares has launched two new autocallable income ETFs linked to Palantir Technologies Inc and Robinhood Markets Inc.  
- These funds, GraniteShares Autocallable PLTR ETF and GraniteShares Autocallable HOOD ETF, are part of the firm’s expanding suite targeting high-demand, income-generating strategies around volatile single stocks.  
- By incorporating autocallable strategies, these ETFs aim to provide periodic income while offering advantages like intraday liquidity and easier access through brokerage platforms.

benzinga_article

Robinhood

Leverage Shares 2X Long HOOD Daily ETF

NVIDIA

Tesla

Strategy

Coinbase

Invesco QQQ Trust

ServiceNow

Salesforce

NVIDIA Corporation

MicroStrategy Pref Shares MSTR 10.0 Perp

Microstrategy Inc Pref Shares STRC 9.0 Perp

MicroStrategy Pref Shares MSTR 8.0 Perp

Palantir, Robinhood Power GraniteShares' New Yield-Focused ETFs With Monthly Payouts

Top investor Danny Vena believes Palantir Technologies (NASDAQ:PLTR) is a buy due to its strong growth trajectory, with Q1 2026 showing 85% year-over-year revenue growth. Despite concerns over its premium valuation, Vena highlights a favorable PEG ratio of ~0.52, suggesting the stock is undervalued. Wall Street consensus rates PLTR as a Moderate Buy, with a 12-month price target indicating a potential 40% upside.

- Palantir Technologies is experiencing strong revenue and profit growth, with Q1 2026 showing 85% year-over-year sales growth of $1.63 billion.  
- Despite concerns over its valuation, investor Danny Vena suggests that the company's robust growth potential and a PEG ratio of around 0.52 indicate it is still a buy.  
- The consensus on Wall Street is a Moderate Buy, reflecting 13 Buys, 4 Holds, and 2 Sells, with a 12-month average price target suggesting a potential upside of nearly 40%.

Tip Ranks

'It's All About the Math,' Says Top Investor About Palantir Stock

IDGT

CLOU

Ignore the Post-Earnings Selloff in Palantir Stock: The AI Revolution Is Just in the ‘Third Inning’

Barchart Option

iShares US Digital Infrastructure and Real Estate ETF

Global X Cloud Computing ETF

Global X Data Center & Dgtl Infrs ETF

SPDR S&P Software

Proshares Big Data Refiners ETF

Pacer Data & Infrastructure Real Estate ETF

ISHRS S&P Glb It

iShares Expanded Tech Software Sector ETF

Franklin Exponential Data ETF

Ignore the Post-Earnings Selloff in Palantir Stock: The AI Revolution Is Just in the ‘Third Inning’

Palantir remains a high-variance AI infrastructure bet where narrative and execution will matter equally over the next decade.

Where could Palantir be in 10 years? The bull and bear cases.

Palantir, a US technology firm, is facing criticism in the UK for its involvement in the NHS, with concerns over privacy and surveillance. Critics, including prominent figures and the British Medical Journal, argue that its data handling undermines NHS values. Despite this, Palantir claims to improve healthcare efficiency, with over 120 trusts using its platform. The debate centers on whether Palantir's technology is a solution to bureaucratic issues or a threat to civil liberties and trust in public institutions.

- Palantir, a US technology company, is facing criticism for its data handling and ties to military operations while also promising improvements to public services, particularly the NHS, where it has secured significant contracts.  
- Critics argue that its involvement undermines privacy and threatens the traditional patient-doctor relationship by centralizing health records, shifting control from GPs to the state.  
- Despite concerns, supporters highlight the efficiency gains from Palantir's technology, suggesting it could address longstanding bureaucratic challenges in the UK's health system.

The telegraph

Machiavellian spy firm or NHS saviour? The US giant love-bombing Britain

Palantir shares are down in 2026 after huge gains over the past three years.

NASDAQ Composite Index

This tech stock has outperformed the Nasdaq 3 years running, but is down 25% in 2026. Is now the time to buy?

Allegiance Financial Group Advisory Services LLC increased its stake in Palantir Technologies Inc. by 104.7% in Q4, owning 7,448 shares valued at $1.32 million. Other institutional investors also adjusted their holdings. Analyst ratings for Palantir include one Strong Buy, seventeen Buy, eleven Hold, and two Sell, with an average target price of $194.68. Recent insider sales included significant transactions by Ryan D. Taylor and Shyam Sankar, reducing their ownership. Palantir's stock is currently down 1.6%.

- Allegiance Financial Group Advisory Services LLC increased its stake in Palantir Technologies by 104.7%, owning 7,448 shares worth $1,324,000.  
- Palantir reported an 84.7% revenue increase year-over-year, with Q1 earnings of $0.33 per share, exceeding estimates.  
- Insider selling and mixed analyst ratings contribute to a volatile sentiment surrounding the stock, which currently has a target price averaging $194.68.

Market Beat

Allegiance Financial Group Advisory Services LLC Increases Stake in Palantir Technologies Inc. $PLTR

Jefferies channels Michael Burry in unveiling a new call to dump Palantir stock

businessinsider

Jefferies channels Michael Burry in unveiling a new call to dump Palantir stock

Direxion Daily PLTR Bear 1X Shares(PLTD.US)

Palantir posts record growth but faces European market loss

Palantir's blowout quarter fails to lift high-priced stock

Palantir, Robinhood Power GraniteShares' New Yield-Focused ETFs With Monthly Payouts

'It's All About the Math,' Says Top Investor About Palantir Stock

Ignore the Post-Earnings Selloff in Palantir Stock: The AI Revolution Is Just in the ‘Third Inning’